MA39909B1 - Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer - Google Patents

Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer

Info

Publication number
MA39909B1
MA39909B1 MA39909A MA39909A MA39909B1 MA 39909 B1 MA39909 B1 MA 39909B1 MA 39909 A MA39909 A MA 39909A MA 39909 A MA39909 A MA 39909A MA 39909 B1 MA39909 B1 MA 39909B1
Authority
MA
Morocco
Prior art keywords
treatment
drug
cancer
igf
antibody
Prior art date
Application number
MA39909A
Other languages
English (en)
Other versions
MA39909A (fr
Inventor
Charlotte Beau-Larvor
Liliane Goetsch
Michel Perez
Ian Rilatt
Matthieu Broussas
Thierry Champion
Alain Robert
Jean-François Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA39909A publication Critical patent/MA39909A/fr
Publication of MA39909B1 publication Critical patent/MA39909B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne un conjugué anticorps-médicament pouvant se lier à l'igf-1r. Selon un aspect, l'invention concerne un conjugué anticorps-médicament comprenant un anticorps pouvant se lier à l'igf-1r, ledit anticorps étant conjugué à au moins un médicament choisi parmi des dérivés de la dolastatine 10 et des auristatines. L'invention concerne également une méthode de traitement et l'utilisation dudit conjugué anticorps-médicament pour le traitement du cancer.
MA39909A 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer MA39909B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
EP15720045.2A EP3134124B1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA39909A MA39909A (fr) 2017-03-01
MA39909B1 true MA39909B1 (fr) 2019-05-31

Family

ID=50630736

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39909A MA39909B1 (fr) 2014-04-25 2015-04-27 Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA047811A MA47811A (fr) 2014-04-25 2015-04-27 Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA047811A MA47811A (fr) 2014-04-25 2015-04-27 Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer

Country Status (27)

Country Link
US (2) US10633448B2 (fr)
EP (2) EP3134124B1 (fr)
JP (1) JP6258523B2 (fr)
KR (1) KR101795984B1 (fr)
CN (1) CN106456800B (fr)
AU (1) AU2015250759B2 (fr)
BR (1) BR112016024619A2 (fr)
CA (1) CA2946469C (fr)
CY (1) CY1121783T1 (fr)
DK (1) DK3134124T3 (fr)
ES (1) ES2727103T3 (fr)
HR (1) HRP20190888T8 (fr)
HU (1) HUE044862T2 (fr)
IL (1) IL248455B (fr)
LT (1) LT3134124T (fr)
MA (2) MA39909B1 (fr)
MX (1) MX2016013704A (fr)
MY (1) MY186711A (fr)
PL (1) PL3134124T3 (fr)
PT (1) PT3134124T (fr)
RS (1) RS58742B1 (fr)
RU (1) RU2692563C2 (fr)
SA (1) SA516380120B1 (fr)
SI (1) SI3134124T1 (fr)
TN (1) TN2016000472A1 (fr)
UA (1) UA120364C2 (fr)
WO (1) WO2015162291A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3134124T1 (sl) * 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
KR20180105634A (ko) 2015-10-26 2018-09-28 피에르 파브르 메디카먼트 Igf-1r을 발현하는 암의 치료를 위한 조성물
US11340233B2 (en) 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
CN113453724A (zh) 2018-09-27 2021-09-28 皮埃尔法布雷医药公司 基于磺酰基马来酰亚胺的连接子和相应的偶联物
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
EP3909612A1 (fr) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition de nanoparticules
WO2023240223A2 (fr) * 2022-06-10 2023-12-14 Acelyrin, Inc. Compositions d'anticorps anti-igf-1r
EP4353220A1 (fr) 2022-10-12 2024-04-17 Pierre Fabre Medicament Utilisation d'une composition aqueuse liquide pour la solubilisation et la stabilisation d'un conjugué anticorps-médicament

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69434136T2 (de) 1993-10-01 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. Dolastatin-derivate
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
US20090068110A1 (en) 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
CA2683568A1 (fr) 2007-05-08 2008-11-20 Genentech, Inc. Anticorps anti-muc16 produits avec de la cysteine et conjugues anticorps-medicament
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
DK2276509T3 (en) 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CA2754531A1 (fr) 2009-03-06 2010-09-30 Seattle Genetics, Inc. Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
WO2012041805A1 (fr) 2010-09-29 2012-04-05 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatines et leur utilisation
JP6121906B2 (ja) * 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
CA2813411C (fr) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Conjugues de polypeptides obtenus par genie biologique, et procede de fabrication correspondants au moyen de transglutaminase
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
US9150644B2 (en) * 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
MX359217B (es) 2011-05-27 2018-09-19 Ambrx Inc Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
SG11201408153YA (en) 2012-06-07 2015-01-29 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
AU2013277169B2 (en) 2012-06-19 2017-02-02 Ambrx, Inc. Anti-CD70 antibody drug conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
US20160106856A1 (en) 2012-08-14 2016-04-21 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2014096551A1 (fr) 2012-12-21 2014-06-26 Glykos Finland Oy Conjugués constitués de molécules de charge utile et de lieurs
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
MX2016013999A (es) 2014-04-25 2017-05-30 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
SI3134124T1 (sl) * 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
KR102357032B1 (ko) * 2014-04-25 2022-02-08 피에르 파브르 메디카먼트 Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
KR20180105634A (ko) * 2015-10-26 2018-09-28 피에르 파브르 메디카먼트 Igf-1r을 발현하는 암의 치료를 위한 조성물

Also Published As

Publication number Publication date
PL3134124T3 (pl) 2019-09-30
RU2016145444A (ru) 2018-05-28
EP3134124B1 (fr) 2019-02-20
CN106456800A (zh) 2017-02-22
JP2017513900A (ja) 2017-06-01
MA47811A (fr) 2019-06-19
LT3134124T (lt) 2019-05-27
MX2016013704A (es) 2017-03-31
US11661457B2 (en) 2023-05-30
US10633448B2 (en) 2020-04-28
EP3134124A1 (fr) 2017-03-01
ES2727103T3 (es) 2019-10-14
HRP20190888T1 (hr) 2019-07-12
TN2016000472A1 (en) 2018-04-04
CA2946469C (fr) 2019-10-29
UA120364C2 (uk) 2019-11-25
RU2016145444A3 (fr) 2018-11-22
BR112016024619A2 (pt) 2017-10-10
SI3134124T1 (sl) 2019-06-28
AU2015250759B2 (en) 2017-11-30
US20170043031A1 (en) 2017-02-16
MA39909A (fr) 2017-03-01
DK3134124T3 (da) 2019-05-06
RU2692563C2 (ru) 2019-06-25
US20200270352A1 (en) 2020-08-27
IL248455B (en) 2020-01-30
JP6258523B2 (ja) 2018-01-10
KR101795984B1 (ko) 2017-11-10
PT3134124T (pt) 2019-06-03
IL248455A0 (en) 2016-11-30
SA516380120B1 (ar) 2019-02-27
MY186711A (en) 2021-08-12
ES2727103T8 (es) 2020-03-02
EP3498301A1 (fr) 2019-06-19
WO2015162291A1 (fr) 2015-10-29
HUE044862T2 (hu) 2019-11-28
CN106456800B (zh) 2018-05-01
CA2946469A1 (fr) 2015-10-29
RS58742B1 (sr) 2019-06-28
CY1121783T1 (el) 2020-07-31
KR20160146817A (ko) 2016-12-21
AU2015250759A1 (en) 2016-11-10
HRP20190888T8 (hr) 2019-10-04

Similar Documents

Publication Publication Date Title
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MA38396A1 (fr) Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
EP4257134A3 (fr) Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
TW200642694A (en) Anti-M-CSF antibody compositions
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
BR112016024363A2 (pt) conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA53069B1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
MA33387B1 (fr) Polypeptides et procede de traitement
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
MA43345A (fr) Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EA202090116A1 (ru) Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения